Modzatinib

Modzatinib (ITK kinase-IN-1) (compound I) is an inhibitor targeting ITK kinase (IC50=8 nM, Jurkat cells) and can be used to study inflammatory diseases. Modzatinib has an IC50 of 23 nM for JAK3 in hPBMC cells (based on IL-2/pSTAT5 levels), wihout inhibitory effect against JAK2[1].

Product Specifications

CAS Number

[2411407-25-3]

Product Name Alternative

ITK kinase-IN-1

UNSPSC

12352005

Target

Itk; JAK

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

FC(F)(C1)[C@H]1C2=CNC3=NC=NC(N[C@H]4CN([C@H](CC4)C)C(C=C)=O)=C23

Molecular Formula

C18H21F2N5O

Molecular Weight

361.39

References & Citations

[1]FRATTINI, et al.Pyrrolopyrimidine compositions in combination with ITK kinase inhibitors for treating inflammatory conditions. World Intellectual Property Organization, WO2024102778 A1. 2024-05-16.